Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -120,088 | -31,781 | -57,107 | -96,132 | -63,778 |
| Depreciation Amortization | 357 | 462 | 738 | 658 | 268 |
| Accounts receivable | -301 | N/A | -87 | 21 | -79 |
| Accounts payable and accrued liabilities | 4 | 1,582 | -1,087 | -218 | 696 |
| Other Working Capital | 44,439 | 1,649 | -6,047 | -930 | 12,042 |
| Other Operating Activity | 75,579 | -8,562 | 4,081 | 17,769 | 12,016 |
| Operating Cash Flow | $-10 | $-36,650 | $-59,509 | $-78,832 | $-38,835 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -412 | -193 | -131 | -1,559 | -1,156 |
| Investing Cash Flow | $-412 | $-193 | $-131 | $-1,559 | $-1,156 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 98,888 | 11,986 | 55,036 | 49,530 | 84,586 |
| Common Stock Repurchased | -552 | -544 | -498 | -546 | -274 |
| Financing Cash Flow | $98,336 | $11,442 | $54,538 | $48,984 | $84,312 |
| Beginning Cash Position | 42,803 | 68,204 | 73,306 | 104,713 | 60,392 |
| End Cash Position | 140,717 | 42,803 | 68,204 | 73,306 | 104,713 |
| Net Cash Flow | $97,914 | $-25,401 | $-5,102 | $-31,407 | $44,321 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10 | -36,650 | -59,509 | -78,832 | -38,835 |
| Capital Expenditure | -412 | -193 | -132 | -1,559 | -1,156 |
| Free Cash Flow | -422 | -36,843 | -59,641 | -80,391 | -39,991 |